

**Solasia Announces episil® oral liquid Launched in South Korea**

Tokyo, Japan, September 23, 2020 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia"), a specialty pharmaceutical company based in Japan, today announced that episil® oral liquid (SP-03, hereinafter "episil®") has been launched in South Korea by its commercialization and promotion partner, Synex Consulting Ltd. (Headquarters: Seoul, South Korea, hereinafter "Synex").

Solasia obtained an exclusive license to develop and commercialize episil® in Japan, China, and South Korea from Sweden-based Camurus AB (STO: CAMX). episil® was launched in Japan in 2018 with the approval of the Ministry of Health, Labour and Welfare (MHLW), and in China in 2019 with the approval of the National Medical Products Administration (NMPA, formerly CFDA). In South Korea, episil® was approved from the National Institute of Medical Device Safety Information (NIDS) in 2019 and now launched by our sales partner, Synex.

The impact of this event has been already included in the current fiscal year's financial forecast, thus no change in financial forecast will be announced as of now. However, the contribution to the company's financials is expected to affect over medium to long term.

**About episil®**

episil® uses the patented FluidCrystal® technology from Camurus AB, Sweden. It is a lipid-based, preservative-free liquid that adhere to the oral mucosa. Clinically demonstrated, episil® has been shown to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours\*. It provides physical protection to the oral sensitive and ulcerated epithelium. episil® is the only ready-to-use, pocket-sized medical device that manages and relieves oral mucositis, expected helping patients suffering from oral pain to improve the quality of life (QOL).

For more information about episil®, please access Camurus AB, episil® website: <https://www.episil.net/>

\* Hadjieva, T et al. Treatment of oral mucositis pain following radiation therapy for head-and-neck cancer using a bioadhesive barrier-forming lipid solution. Support Care Cancer 2014, 22:1557-1562

**About Solasia**

Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers.

For more information about the company, please visit [www.solasia.co.jp/en/](http://www.solasia.co.jp/en/)

**About Synex**

Synex started as a regulatory consulting firm for healthcare products and has since expanded its service scope continually. We have leveraged those consulting competencies to further boost ourselves to a total market access solution firm for importing and distributing medical products in South Korea.

The firm currently maintains over 100 product licenses for more than 20 global healthcare manufacturers. In addition, in terms of distributing business, Synex not only directly distributes healthcare products to customers including hospitals, wholesalers, and others, but also provides clinical support, technical support, marketing, and logistics toward medical products.

For more information about the company, please visit <http://www.synex.co.kr/>

###

(Contact)

**Solasia Pharma K.K.**

Rie Toyoda, Public Relations and Investor Relations

Tel: +81 3 5843 8049 (Japan)

[info@solasia.co.jp](mailto:info@solasia.co.jp)